Drug repurposing against SARS-CoV-2 using computational approaches

Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion

“…On the other hand, several FDA-approved drugs had been repurposed for combating COVID-19 with acceptable side effects in human [57] , [58] , [59] , [60] , [61] , [62] ; however, only some of which were reported with beneficial effects in hospitalized COVID-19 patients. For example, Remdesivir, a nucleoside drug against a variety of viruses, helps to shorten the recovery time of hospitalized COVID-19 patients [23] .…”

Drug repurposing: An effective strategy to accelerate contemporary drug discovery

“…Among the hits identified by computational methods, 35 candidates were suggested for further development, among which ten drugs are in clinical trials (Phase III and IV) for treating SARS-CoV-2 infection. 9 …”

Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2

“…11 During the initial stages of the COVID-19 pandemic, medications approved for other diseases were used as a supportive care. 12,13 Current research studies are focus on the importance of main protease (Mpro or 3CLpro) for discovering possible therapeutic for SARS-CoV-2. Additionally, among the SARS-CoV-2 mutant strains, nearly no mutations have been found in the Mpro active region, making this enzyme a promising therapeutic target.…”